Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 2
1948 1
1949 2
1950 5
1951 4
1952 13
1953 8
1954 17
1955 4
1956 17
1957 11
1958 24
1959 21
1960 28
1961 37
1962 117
1963 86
1964 57
1965 71
1966 92
1967 109
1968 111
1969 134
1970 147
1971 205
1972 200
1973 230
1974 236
1975 268
1976 293
1977 278
1978 349
1979 343
1980 338
1981 393
1982 378
1983 414
1984 469
1985 609
1986 609
1987 823
1988 921
1989 1093
1990 1137
1991 1184
1992 1317
1993 1529
1994 1771
1995 1934
1996 2255
1997 2598
1998 3176
1999 3633
2000 4636
2001 5320
2002 5996
2003 7138
2004 8569
2005 10164
2006 11538
2007 13237
2008 15197
2009 17412
2010 20476
2011 23556
2012 26090
2013 28305
2014 30226
2015 32162
2016 32709
2017 33224
2018 33967
2019 35138
2020 38917
2021 42368
2022 35621
2023 208
Text availability
Article attribute
Article type
Publication date

Search Results

484,529 results
Results by year
Filters applied: . Clear all The following term was not found in PubMed: Soobae
Page 1
KIM-1/TIM-1 is a Receptor for SARS-CoV-2 in Lung and Kidney.
Mori Y, Fink C, Ichimura T, Sako K, Mori M, Lee NN, Aschauer P, Padmanabha Das KM, Hong S, Song M, Padera RF, Weins A, Lee LP, Nasr ML, Dekaban GA, Dikeakos JD, Bonventre JV. Mori Y, et al. medRxiv. 2022 Jan 11:2020.09.16.20190694. doi: 10.1101/2020.09.16.20190694. Preprint. medRxiv. 2022. PMID: 32995803 Free PMC article.
Uptake was inhibited by anti-KIM-1 antibodies and TW-37, a newly discovered inhibitor of KIM-1-mediated endocytosis. ...Thus, KIM-1 is an alternative receptor to ACE2 for SARS-CoV-2. KIM-1 targeted therapeutics may prevent and/or treat COVID-19....
Uptake was inhibited by anti-KIM-1 antibodies and TW-37, a newly discovered inhibitor of KIM-1-mediated endocytosis. ...Thus, …
Endometrial Cancer.
Kim SI, Kim JW. Kim SI, et al. N Engl J Med. 2021 Feb 11;384(6):586. doi: 10.1056/NEJMc2035378. N Engl J Med. 2021. PMID: 33567203 No abstract available.
Reply.
Kim JH. Kim JH. Retina. 2021 Sep 1;41(9):e60-e61. doi: 10.1097/IAE.0000000000003189. Retina. 2021. PMID: 33840793 No abstract available.
Profile.
Kim JH. Kim JH. Hum Vaccin Immunother. 2016;12(2):554-5. doi: 10.1080/21645515.2015.1132687. Hum Vaccin Immunother. 2016. PMID: 26766624 Free PMC article. No abstract available.
Correspondence.
Kim JH. Kim JH. Retina. 2016 Aug;36(8):e89. doi: 10.1097/IAE.0000000000001189. Retina. 2016. PMID: 27388730 No abstract available.
KIM-1-mediated anti-inflammatory activity is preserved by MUC1 induction in the proximal tubule during ischemia-reperfusion injury.
Al-Bataineh MM, Kinlough CL, Mi Z, Jackson EK, Mutchler SM, Emlet DR, Kellum JA, Hughey RP. Al-Bataineh MM, et al. Am J Physiol Renal Physiol. 2021 Aug 1;321(2):F135-F148. doi: 10.1152/ajprenal.00127.2021. Epub 2021 Jun 21. Am J Physiol Renal Physiol. 2021. PMID: 34151589 Free PMC article.
As both KIM-1 and MUC1 are induced in the proximal tubule (PT) during IRI and are a disintegrin and metalloprotease 17 (ADAM17) substrates, we tested the hypothesis that MUC1 protects KIM-1 activity. ...Compared with WT mice, Muc1 KO mice had higher urinary KIM
As both KIM-1 and MUC1 are induced in the proximal tubule (PT) during IRI and are a disintegrin and metalloprotease 17 (ADAM17) subst …
Reply.
Kim M, Lee DH, Koh HJ, Lee SC, Kim SS. Kim M, et al. Retina. 2016 Jun;36(6):e48. doi: 10.1097/IAE.0000000000001068. Retina. 2016. PMID: 27203788 No abstract available.
Kim et al. reply.
Kim SW, Kim KH, Sagawa T, De Liberato S, Ueda M. Kim SW, et al. Phys Rev Lett. 2013 Nov 1;111(18):188902. doi: 10.1103/PhysRevLett.111.188902. Epub 2013 Oct 30. Phys Rev Lett. 2013. PMID: 24237571 No abstract available.
Overview.
Kim JH. Kim JH. Semin Fetal Neonatal Med. 2022 Oct 29:101397. doi: 10.1016/j.siny.2022.101397. Online ahead of print. Semin Fetal Neonatal Med. 2022. PMID: 36402719 No abstract available.
484,529 results
You have reached the last available page of results. Please see the User Guide for more information.